Background and objectives Increased visit-to-visit variability of BP is associated with cardiovascular disease risk. We examined the association of visit-to-visit variability of BP with renal outcomes among 21,245 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Introduction
Numerous studies have shown the association of higher mean BP and renal outcomes (1) (2) (3) . BP variability across visits has traditionally been considered random fluctuation around the underlying BP, which might attenuate observed relationships between BP and outcomes (4, 5) .
Recently, observations that visit-to-visit variability (VVV) of BP is associated with a higher risk for stroke, coronary heart disease, and mortality have increased interest in BP variability as a prognostic indicator itself (6) (7) (8) . In some but not all studies, persons with higher BP variability had more rapid CKD progression as measured by declines in eGFR or increases in urinary albumin (9) (10) (11) (12) (13) . Some studies of persons with diabetes have shown an association of BP variability with more clinically impactful renal outcomes, including ESRD (10, 14) , but such an association has not been shown among persons without diabetes.
To better understand the association of BP variability with renal outcomes in the broader population, we analyzed data from the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT) (15) . Because data on eGFR and ESRD were collected routinely during a prolonged period of follow-up, the ALLHAT data provide a valuable opportunity to test the hypothesis that BP variability, as measured by VVV, is associated with clinically relevant renal outcomes.
Materials and Methods
ALLHAT was a randomized, double-blind trial sponsored by the National Heart, Lung, and Blood Institute (Trial Registration: ClinicalTrials.gov NCT00571038). As described in prior publications (15, 16) , ALLHAT was designed to determine whether treatment with a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), or an a-blocker (doxazosin), each compared with treatment with a diuretic (chlorthalidone), would lower major cardiovascular disease (CVD) outcomes. Between February of 1994 and January of 1998, 42,418 hypertensive adults ages $55 years old with one or more additional risk factors for CVD were enrolled at 623 clinical sites. Exclusion criteria included history of symptomatic heart failure, known left ventricular ejection fraction ,35%, or serum creatinine level of $2 mg/dl. The doxazosin arm was discontinued in 2000 because of little chance of finding a coronary heart disease benefit and a higher risk of CVD compared with the chlorthalidone arm (17) . Active follow-up of participants randomized to chlorthalidone, amlodipine, or lisinopril ended in February of 2002 (18) . ALLHAT was approved by local institutional review boards; all participants provided written informed consent. This analysis was approved by the University of Alabama-Birmingham Institutional Review Board.
Study Visits, BP Measurements, and Calculation of VVV of BP
To calculate VVV of BP, we used data from seven followup visits that occurred 6, 9, 12, 16, 20, 24 , and 28 months after randomization. We started at the 6-month follow-up visit to avoid potential confounding by BP changes that occurred between randomization and that visit (mean BP fell by approximately 8/5 mmHg). To increase the precision of VVV of BP estimates, we restricted our primary analysis to participants with at least five BP measurements from months 6 to 28 (19) . At each follow-up visit, BP was measured twice following a standardized technique; the two results were averaged for analysis. For the primary analysis, we used the intraindividual SD of systolic BP across visits (SD_SBP) as our measure of VVV of BP. We also calculated average real variability and identified the peak value as alternative measures of VVV of BP. Average real variability summarizes variability between BP values at consecutive visits by taking the mean of the absolute difference between adjacent visits-it is less affected by trends in measures than SD; peak value (the highest systolic BP [SBP] among the 6-, 9-, 12-, 16-, 20-, 24-, and 28-month measures minus the mean of SBP across these visits) is a sensitive measure of spikes in BP (20) .
Outcome Ascertainment
Our composite primary outcome was the development of ESRD or a $50% decrease in eGFR. We used the US Renal Data System (USRDS) (21) to identify persons who developed ESRD after the assessment of VVV of BP. We followed participants from their 28-month visit to the date of ESRD, death, or loss to follow-up for a maximum of 72 months after randomization. We calculated eGFR at 24, 48, and 72 months after randomization using the Chronic Kidney Disease Epidemiology Study equation (22) and then identified participants with a $50% decline in eGFR between the month 24 and 72 study visits. For participants missing eGFR at month 72, we used percentage decline in eGFR between months 24 and 48 if available. Although the baseline eGFR measured at month 24 preceded the final BP measure used to calculate VVV of BP (i.e., month 28), we believed that the benefit of using seven visits in calculating VVV of BP outweighed this small period of overlap.
Covariate Information
We selected potential confounding variables collected at the baseline ALLHAT visit. These included age; sex; race; ethnicity; body mass index; geographic region; education; history of type 2 diabetes; HDL-cholesterol ,35 mg/dl; myocardial infarction, stroke, or other atherosclerotic CVD; known left ventricular hypertrophy (LVH); ST depression or T-wave inversion on baseline electrocardiogram; cholesterol; randomization group; cigarette smoking; antihypertensive medication use; and aspirin use. We averaged the eGFR measured prerandomization and 2 months after randomization to obtain the baseline eGFR. Finally, we used data collected at visits conducted 6-28 months after randomization to calculate the following covariates: mean SBP and diastolic BP (DBP), pulse pressure, use of antihypertensive medications beyond the randomization drug, changes in antihypertensive medication regimen (adding, stopping, or changing antihypertensive medications), statin use, number of study visits available to calculate VVV, and low adherence defined as participant report of taking ,80% of the randomization drug at any visit between months 6 and 28. Prior studies suggest that this threshold is associated with clinically relevant end points, such as hypertension control (23) .
Study Population
Because of limited follow-up of participants randomized to doxazosin, we restricted our analyses to 33,357 ALLHAT participants randomized to the chlorthalidone, amlodipine, or lisinopril arms. Of these participants, 24,004 had at least five BP measurements during months 6-28 after randomization. We also excluded 511 participants enrolled in Canada, because ascertainment of ESRD relied on the USRDS. We excluded 1681 participants with a CVD end point (stroke, myocardial infarction, coronary artery bypass surgery, congestive heart failure, or peripheral vascular revascularization), ESRD, or death before month 28 (6,7) and 567 participants who lacked both baseline and 1-to 3-month values for eGFR, a key risk factor for ESRD, leaving 21,245 participants for our primary analyses ( Figure 1 ). We conducted a secondary analysis among 13,886 participants who had eGFR at 24 months and either 48 or 72 months after randomization, thus having the opportunity to have both components of the composite outcome.
Statistical Analyses
We first calculated characteristics of 21,245 included participants stratified by quintile of SD_SBP. We used chisquared tests to compare categorical variables and ANOVA to compare continuous variables across quintiles.
We used a series of interval-censored regression models to calculate the adjusted hazard ratios for the composite outcome of ESRD or a $50% decline in eGFR by quintile of SD_SBP. These models account for the fact that we do not know the precise date that our outcome occurred (i.e., we only know if eGFR declined by $50% when we measure eGFR at the month 48 and 72 follow-up visits but not the date between visits) (24) . For participants who died before experiencing an event, censoring occurred on their date of death. We included available variables with a known or plausible association with SD_SBP and risk of renal end points as confounders. To better understand the importance of each class of confounders, we constructed five nested models. Model 1 included adjustment for demographics, region, and randomization assignment (amlodipine, lisinopril, or chlorthalidone). Model 2 added adjustment for education, smoking, body mass index, diabetes, total cholesterol, history of CVD, history of atrial fibrillation, major ST depression or T-wave inversion on electrocardiogram, LVH, low HDL-cholesterol, aspirin use, antihypertensive medication use before study randomization, and statin use during the VVV of SBP assessment period. Model 3 additionally included mean SBP, pulse pressure, and medication adherence, all measured during month 6 through month 28 of follow-up. Model 4 also included the number of visits used to calculate SD_SBP, use of additional antihypertensive medication, and changes in antihypertensive medication regimen during this period. Finally, model 5 added baseline eGFR. We calculated the statistical significance of trends across quintiles by modeling the median SD_SBP within each quintile as a continuous variable. We conducted similar analyses for the outcomes of ESRD and $50% decline in eGFR separately. For analyses using ESRD as the outcome, we used Cox proportional hazards models, because the dates on which the outcome occurred were available.
We then performed a series of sensitivity analyses. First, we repeated the analyses including only participants (n=13,886) who had measures of eGFR at both 24 months and 48 or 72 months after randomization. Second, we repeated the analyses using alternate measures (average real variability and peak value) of VVV of SBP and using VVV of DBP measured by SD, average real variability, and peak value. Third, we calculated the association of SD_SBP with the composite primary end point in subgroups defined by (1) mean SBP during months 6-28 postrandomization, (2) baseline eGFR, (3) diabetes mellitus diagnosis, and (4) randomized drug (amlodipine, chlorthalidone, or lisinopril).
Finally, we examined the association of SD_SBP with ESRD identified by the USRDS through December of 2006 (#10.5 years after the SD_SBP assessment period). Proportional hazards assumptions were tested by including SD_SBP by time (log-transformed) interaction terms in our models. The assumption of proportional hazards was violated for this analysis (P=0.01). Therefore, we present the hazard ratios during the first 3.7 years after the SD_SBP assessment period (i.e., in-trial ESRD events) and after 3.7 years (i.e., post-trial ESRD events). All analyses were conducted in Stata 13.1 (StataCorp., College Station, TX).
Results

Baseline Characteristics
Characteristics of ALLHAT participants included and excluded from our analysis are provided in Supplemental Table 1 . Characteristics of included participants are presented by quintile of SD_SBP in Table 1 . Older age, women, non-Hispanic black race, current smoking, major ST depression or T-wave inversion, LVH, and use of antihypertensive medication before baseline were associated with higher SD_SBP. In contrast, the prevalence of low HDL-cholesterol and aspirin use at baseline was lower at higher SD_SBP. Baseline cholesterol, mean SBP, and pulse pressure were higher, whereas baseline eGFR was lower at higher levels of SD_SBP. Higher mean SBP, DBP, and pulse pressure during the period of SD_SBP assessment were associated with higher SD_SBP. Additionally, those with higher SD_SBP were less likely to be taking a statin but were taking more classes of antihypertensive medications and were more likely to have low adherence and change medication classes. Participants randomized to lisinopril as opposed to chlorthalidone or amlodipine were more likely to be in the highest quintile of SD_SBP.
Association of SD_SBP with Renal Outcomes
Over a mean of 3.5 years of follow-up after the SD_SBP assessment period, 297 participants experienced outcomes; 161 participants developed ESRD, and 173 had a 50% decline in EGFR-37 had both events. The risk of the composite end point of ESRD or a $50% decline in eGFR was higher in higher quintiles of SD_SBP (Table 2) . After full multivariable adjustment, this trend remained statistically significant. Higher SD_SBP was also associated with higher risk of each end point analyzed separately, although the association with ESRD was not statistically significant (P=0.06). As shown in Table 3 , results were similar when analyses were restricted to 13,886 ALLHAT participants with eGFR measured at 24 months postrandomization and either 48 or 72 months postrandomization (i.e., those with data to assess a $50% decline in eGFR). Higher Figure 1 . | Summary of analytic cohort formation. ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; CHD, coronary heart disease; CHF, congestive heart failure. ,0.001 risk for the composite outcome was associated with higher SD_SBP in subgroups defined by mean SBP during the 6-to 28-month follow-up visits, randomization group, baseline eGFR, and diabetes mellitus (Supplemental Table 2 ). The magnitude of the association between renal outcomes and quintiles of SD_SBP was slightly less than the association between renal outcomes and mean SBP (Supplemental Table 3 ).
Association of Alternative Measures of VVV of BP
The association of VVV of BP with renal outcomes was qualitatively similar when we used average real variability or peak value of SBP, although the association was not statistically significant for all end points (Supplemental Table 4 ). Although VVV of DBP was associated with the composite and individual end points in models adjusting only for baseline characteristics, the associations were not statistically significant in fully adjusted models (Supplemental Table 5 ).
Association of VVV of SBP with ESRD during Longer-Term Follow-Up
During extended follow-up through December of 2006, 439 participants developed ESRD. Although the association of SD_SBP ESRD approached significance (P=0.06) during the in-trial period (i.e., 3.7 years after the SD_SBP assessment), there was no such trend after this time point (Table 4) .
Discussion
We showed an association between higher SD_SBP and higher risk of renal outcomes similar in magnitude to the association that has been seen for the association of SBP variability with CVD outcomes (6, 7, 10) ; the association persisted after multivariable adjustment for important potential confounders, including baseline eGFR and mean BP. An association also tended to be present for average real variability and peak value, two alternative measures of SBP variability. These data add to the evidence that SBP variability is a risk factor for renal outcomes as well as CVD (25) , dementia (26, 27) , and all-cause mortality (28) .
Since Rothwell et al. (6) showed the association between BP variability and cardiovascular end points, several studies have examined the relationship between BP variability and renal outcomes. Most recently, Yano et al. (13) showed that higher SBP variability was associated with the development of proteinuria or eGFR,60 ml/min per 1.73 m 2 among 48,587 Japanese adults without CKD or diabetes. However, studies showing a higher risk for advanced renal disease, such as ESRD, have been restricted to persons with diabetes. An analysis of individuals participating in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial, all of whom had diabetes, found increasing risk for the combined end point of new macroalbuminuria (.300 mg albumin per 1 g creatinine), doubling of serum creatinine, need for RRT, or renal death with increasing decile of SBP variability (10) . However, this analysis did not adjust for baseline renal function or albuminuria. An analysis of combined data from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan Trial ,0.01
We used interval-censored regression models to calculate hazard ratios in the first and third outcomes. We used Cox proportional hazard models in the second outcome. Model 1 includes adjustment for age, sex, race/ethnicity, region of residence, and randomization assignment. 
0.001
We used interval-censored regression models to calculate hazard ratios in the first and third outcomes. We used Cox proportional hazard models in the second outcome. Model 1 includes adjustment for age, sex, race/ethnicity, region of residence, and randomization assignment. and the Irbesartan Diabetic Nephropathy Trial showed that SBP variability was associated with risk for ESRD and other renal end points, even after adjusting for baseline renal disease. However, this study was restricted to patients with diabetes with .500 mg/d albumin excretion (14) . We now extend these results to show that SBP variability is associated with renal outcomes, including ESRD, among nonpatients with diabetes. Several features of the ALLHAT cohort allowed us to incorporate important methodologic strengths. We required participants to have at least five BP measurements performed using standard techniques at visits scheduled for months 6, 9, 12, 16, 20, 24, or 28 ; this use of multiple, rigorously measured BP values obtained at relatively even intervals likely provides a more reliable estimate of BP variability than most prior studies (19) . Our large sample size and prolonged follow-up allowed us to use clinically meaningful end points occurring after BP variability was measured.
We were also able to show that the association between SBP variability and renal outcomes was similar among important subgroups defined by baseline BP control, baseline eGFR, the presence or absence of diabetes, and the class of drug being used. The ALLHAT's extended ESRD follow-up also allowed us to determine that SBP variability was not associated with ESRD that developed .3.7 years after the period when SBP variability was ascertained. This suggests that BP variability has less predictive power for end points that follow measurement for a long time than for more proximate end points. Finally, we found that the magnitude of the association of SBP variability with renal outcomes is nearly as large as that of mean SBP, a well established risk factor for renal outcomes (3) .
Given the consistency of our findings, we considered potential etiologies. Some authors have suggested that variable medication adherence explains the association between BP variability and various cardiovascular end points (25) . However, prior work suggests that adherence explains only a small percentage of BP variability (29) . In this analysis, the association of SBP variability with renal end points persisted after adjustment for medication adherence. Alternatively, increased BP variability may reflect vascular dysfunction, such as increased arterial stiffness (30, 31) , endothelial dysfunction (32), or increased vascular inflammation (33) . Similarly, autonomic dysfunction could lead to increased BP variability while increasing the risk of vascular events (34) .
Although the ALLHAT data have numerous strengths, there are also limitations. First and most obviously, because this was an observational study, the association that we found between SBP variability and renal end points may not be causal. Indeed, reverse causality is plausible, because persons with more significant renal disease might have greater BP variability. However, we did restrict outcome ascertainment to the period after we measured BP variability, with the exception that we used the month 28 measure of BP in our calculation of BP variability but used the month 24 eGFR as the baseline in our calculation of 50% decline in eGFR. Second, we excluded approximately 32% of the ALLHAT participants who did not have five or more BP measurements during the BP variability assessment period or who did not have baseline serum creatinine measurement. Moreover, for 35% of our analyzed cohort, we did not have data needed to identify a 50% decrease in eGFR during follow-up. However, a secondary analysis using only 13,886 persons for whom this end point could be calculated gave similar results as did analyses using only ESRD as an end point. Third, many participants changed their antihypertensive regimen during the period when we ascertained BP variability; the association with renal end points persisted, despite adjusting for such changes. Fourth, although we adjusted for many potential confounders, there could be other unobserved confounders. For example, we did not have a measure of albuminuria, which has been related to both renal outcomes and BP variability. It is possible that BP variability simply identifies persons with albuminuria, which is the actual marker of higher risk for renal outcomes; this was not the case in a prior study among patients with diabetes (14) .
Despite these limitations, the association between BP variability and renal outcomes in this study and prior studies warrants several steps. First, studies are needed to identify the mechanisms underlying high BP variability and its relationship with renal outcomes. Second, prospective studies should examine whether inclusion of BP variability in risk calculations can improve decision making regarding CKD risk reduction strategies. Third, studies should examine whether targeting elevated BP variability as well as mean BP can lower the risk for CKD progression over strategies focused solely on mean BP.
